MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
HSTO - Histogen Inc
$1.12
-0.09(-7.44%)8:59:00 PM 2/26/2021
Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Related Peers

Stock news

    02/16/2021HSTO
    Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

    HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) today announced week 26 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 26 timepoint, patients treated with HST-001 demonstrated statistically significant change from baseline in total hairs (terminal and vellus) in the target area (TAHC) ...

    01/19/2021HSTO
    Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

    SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the company’s Investigational New Drug (“IND”) application package for the planned Phas...

    01/7/2021HSTO
    DLA Piper advises Histogen in its US$14 million upsized public offering

    DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share.

    01/6/2021HSTO
    Histogen to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

    SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. Presentation Details The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:00 a....

    01/5/2021HSTO
    Histogen Announces Closing of $14.0 Million Upsized Public Offering

    SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has closed its previously announced public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,0...

    12/31/2020HSTO
    Histogen Announces Pricing of $14.0 Million Upsized Public Offering

    SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has it has priced a public offering of an aggregate of 14,000,000 shares of common stock (or common stock equivalents offered through the issuance of pre-funded warrants), together with accompanying warrants to p...

    12/17/2020HSTO
    Histogen Announces Filing an Investigational New Drug Application for HST-003

    Phase 1/2 Trial Initiation for Knee Cartilage Regeneration Anticipated in First Quarter 2021$2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical DevelopmentSAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function today announced that it has submitted...